Bullish Sun Pharma; see over 20% rise by Dec ’16: JP Morgan
While JP Morgan warns of volatile quarterly results owing to one-time charges, it says the potential upside from the Ranbaxy deal in the medium-term (synergies from FY17 onwards) does strengthen the case for buying the stock at current levels.